

LacR

**SIRT6**

GFP

**DDR?**

**H2AX**

**Wortmannin**



**Figure 6- figure supplement 3**

**Figure 6- figure supplement 3**

**(A)** Schematic representation of the Tethering assay with inhibition of signaling using Wortmannin. **(B-E)** Co-localization with SIRT6-LacR-GFP or GFP/Cherry-LacR after 24h with or without Wortmannin, averages of 3 experiments +/- SEM: **(B)** Co-localization with ɤH2AX (0µM: n[SIRT6]=43, n[GFP]=41; 1µM: (n[SIRT6]=42, n[GFP]=42; 10µM: (n[SIRT6]=42, n[GFP]=41). **(C)** Co-localization with 53BP1 (0µM: n[SIRT6]=32, n[GFP]=32; 1µM: n[SIRT6]=30, n[GFP]=32; 10µM: n[SIRT6]=33, n[GFP]=31). **(D)** Co-localization with BRCA1 (0µM: n[SIRT6]=30, n[GFP]=32; 1µM: n[SIRT6]=31, n[GFP]=31; 10µM: n[SIRT6]=32, n[GFP]=31). **(E)**  Co-localiztion with Ku80-Flag (0µM: n[SIRT6]=45, n[Cherry]=53, 10µM: n[SIRT6]=45, n[Cherry]=58) or MRE11-Flag (0µM: n[SIRT6]=50, n[Cherry]=56, 10µM: n[SIRT6]=60, n[Cherry]=51).

(\*=p<0.05, \*\*=p<0.005, \*\*\*=p<0.0005, \*\*\*\*=p<0.00005).

**A.**

**B.**

**C.**

**D.**

**E.**